Bethe U - Search Results

1

Immunogenicity, reactogenicity, and safety of a second booster with BNT162b2 or full-dose mRNA-1273: A randomized VACCELERATE trial in adults aged ≥75 years (EU-COVAT-1-AGED Part B).

Stemler J, Yeghiazaryan L, Stephan C, Mohn KG, Carcas-Sansuan AJ, Rodriguez ER, Moltó J, Mitxeltorena IV, Welte T, Zablockienė B, Akova M, Bethe U, Heringer S, Salmanton-García J, Jeck J, Tischmann L, Zarrouk M, Cüppers A, Biehl LM, Grothe J, Mellinghoff SC, Nacov JA, Neuhann JM, Sprute R, Frías-Iniesta J, Negi R, Gaillard C, Saini G, León AG, Mallon PWG, Lammens C, Hotterbeekx A, Loens K, Malhotra-Kumar S, Goossens H, Kumar-Singh S, König F, Posch M, Koehler P, Cornely OA; EU-COVAT-1 AGED study group on behalf of the VACCELERATE consortium. Stemler J, et al. Among authors: bethe u. Int J Infect Dis. 2024 Sep;146:107161. doi: 10.1016/j.ijid.2024.107161. Epub 2024 Jul 9. Int J Infect Dis. 2024. PMID: 38992789 Free article. Clinical Trial.

2

Ceftriaxone and cefotaxime are equally effective in the treatment of neutropenic fever.

Cornely OA, Salzberger B, Bethe U, Seifert H, Fätkenheuer G, Diehl V, Schrappe M. Cornely OA, et al. Among authors: bethe u. Antibiot Chemother (1971). 2000;50:37-46. doi: 10.1159/000059315. Antibiot Chemother (1971). 2000. PMID: 10874453 Clinical Trial. No abstract available.

3

Randomized controlled monocentric comparison of once daily ceftriaxone with tobramycin and cefotaxime three times daily with tobramycin in neutropenic fever.

Cornely OA, Bethe U, Salzberger B, Franzen C, Hartmann P, Steinmetz T, Fätkenheuer G, Seifert H, Diehl V, Schrappe M. Cornely OA, et al. Among authors: bethe u. Ann Hematol. 2001 Feb;80(2):103-8. doi: 10.1007/s002770000247. Ann Hematol. 2001. PMID: 11261319 Clinical Trial.

4

A novel type of metastatically spreading subcutaneous aspergillosis without epidermal lesions following allogeneic stem cell transplantation.

Cornely OA, Pels H, Bethe U, Seibold M, Toepelt K, Soehngen D, Ritzkowsky A. Cornely OA, et al. Among authors: bethe u. Bone Marrow Transplant. 2001 Nov;28(9):899-901. doi: 10.1038/sj.bmt.1703250. Bone Marrow Transplant. 2001. PMID: 11781653

5

A randomized monocentric trial in febrile neutropenic patients: ceftriaxone and gentamicin vs cefepime and gentamicin.

Cornely OA, Bethe U, Seifert H, Breuer K, Schütt-Gerowitt H, Salzberger B, Schrappe M, Fätkenheuer G. Cornely OA, et al. Among authors: bethe u. Ann Hematol. 2002 Jan;81(1):37-43. doi: 10.1007/s00277-001-0392-9. Epub 2001 Dec 14. Ann Hematol. 2002. PMID: 11807634 Clinical Trial.

6

Peripheral Teflon catheters: factors determining incidence of phlebitis and duration of cannulation.

Cornely OA, Bethe U, Pauls R, Waldschmidt D. Cornely OA, et al. Among authors: bethe u. Infect Control Hosp Epidemiol. 2002 May;23(5):249-53. doi: 10.1086/502044. Infect Control Hosp Epidemiol. 2002. PMID: 12026149

7

Outcomes of nosocomial bloodstream infections in adult neutropenic patients: a prospective cohort and matched case-control study.

Wisplinghoff H, Cornely OA, Moser S, Bethe U, Stützer H, Salzberger B, Fätkenheuer G, Seifert H. Wisplinghoff H, et al. Among authors: bethe u. Infect Control Hosp Epidemiol. 2003 Dec;24(12):905-11. doi: 10.1086/502158. Infect Control Hosp Epidemiol. 2003. PMID: 14700405

8

Once-daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia.

Cornely OA, Wicke T, Seifert H, Bethe U, Schwonzen M, Reichert D, Ullmann AJ, Karthaus M, Breuer K, Salzberger B, Diehl V, Fätkenheuer G. Cornely OA, et al. Among authors: bethe u. Int J Hematol. 2004 Jan;79(1):74-8. doi: 10.1007/BF02983537. Int J Hematol. 2004. PMID: 14979482 Clinical Trial.

9

Mobile PCR-based surveillance for SARS-CoV-2 to reduce visiting restrictions in nursing homes during the COVID-19 pandemic: a pilot study.

Stemler J, Kramer T, Dimitriou V, Wieland U, Schumacher S, Sprute R, Oberste M, Wiesmüller G, Rau H, Pieper S, Bethe U, Lehmann C, Hellmich M, Klein F, Langebartels G, Cornely OA. Stemler J, et al. Among authors: bethe u. Infection. 2022 Jun;50(3):607-616. doi: 10.1007/s15010-021-01716-4. Epub 2021 Oct 20. Infection. 2022. PMID: 34669164 Free PMC article.

10

EQUAL Trichosporon Score 2022: an ECMM score to measure QUALity of the clinical management of invasive Trichosporon infections.

Sprute R, Bethe U, Chen SC, Cornely OA. Sprute R, et al. Among authors: bethe u. J Antimicrob Chemother. 2022 May 29;77(6):1779-1784. doi: 10.1093/jac/dkac085. J Antimicrob Chemother. 2022. PMID: 35325146 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

30 results

Search Page

Filters